Immuneering appoints Diana F. Hausman, M.D. to Board of Directors

Immuneering Corp

Dr. Hausman appointed Class I Director effective January 14, 2022; Board now has six members.
She brings over 20 years of clinical drug development experience, including CMO roles at Zymeworks and Oncothyreon.
Currently Chief Medical Officer of Lengo Therapeutics, a wholly-owned subsidiary of Blueprint Medicines (Nasdaq: BPMC).
No committee assignment yet; will receive standard non-management director compensation.
Her expertise in oncology and RAS mutant solid tumors supports lead candidate IMM-1-104 development.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Diana F. Hausman, MD

Class I Director

IMRX · Immuneering Corp

Effective: 2022-01-14
Filed: January 18, 2022, 6:59 PM ET

On January 14, 2022, the Board of Directors of Immuneering Corporation (the “Company”) appointed Diana F. Hausman, MD to serve as a member of the Board of Directors as a Class I Director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Diana F. Hausman, MD was appointed as Class I Director at Immuneering Corp.

Action: appointed
Role: Class I Director

Exact text from the filing

On January 14, 2022, the Board of Directors of Immuneering Corporation (the “Company”) appointed Diana F. Hausman, MD to serve as a member of the Board of Directors as a Class I Director.

View on SEC.gov

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-004651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.